BioAge Labs Inc.
BIOA
NASDAQ·Healthcare·Biotechnology·Mkt cap $361.1M
$9.59
▲ +0.95%
P/E
-4.03
Mkt Cap
$361.1M
52-Wk Range
$4.68–$25.96
52-Week Range
$4.68 - $25.96
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 88.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary aging-focused technology platform for target identification
- Differentiated human datasets providing molecular insights into aging mechanisms
- First-mover advantage in combining obesity treatments with geriatric populations
- Oral, small-molecule approach enabling accessibility and patient compliance
Bear Case
1 risk
- Average volatility.
Growth
Revenue decline expected
Expanding obesity treatment market with aging demographic focus
Value
Trading at 0.0x Biotech & Therapeutics peers — a discount despite the growth profile.
Momentum
Falling
-38.2% over 3m
Quality
Excellent
Emerging growth company (2% revenue growth). Early stage with higher risk.
Dividend
None
No dividend
Smart-money signal
Who's buying BIOA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 5, 2026
Reported EPS of -$0.58 vs -$0.65 consensus (+10.8% surprise). Revenue of $2.5M vs $1.5M expected (+63.6%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+10.8%
Revenue trend · last 8Q
—
—
—
—
—
—
+91%
+2%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$1.5M
$2.4M
$2.1M
$3.1M
$2.8M
$2.5M
Margins · last 8Q
Gross
0.0%
Profit
-1064.8%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Roth Capital · Jul 31, 2026
vs Industry
How BIOA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related